Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.46 |
| ▸ | GABRD | O14764 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.46 |
| ▸ | GABRE | P78334 | 2/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503171 | 0.83 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10465814 | 0.81 | GABRP (0.35) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7788149 | 0.80 | GABRP (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30968742 | 0.77 | GABRP (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1819716 | 0.77 | GABRP (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28276724 | 0.75 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL13313461 | 0.72 | HPGD (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1769880 | 0.72 | KDM4E (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL20765628 | 0.72 | NNMT (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL19857487 | 0.72 | KDM4E (0.60) | KDM4EALDH1A1L3MBTL1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1352629-B1 | Use of a pyridine-dicarboxylic acid derivative or a salt thereof to stimulate or induce keratinic fiber growth and/or to prevent its loss | OREAL (FR) | 2011-06-22 | — | — | EP | claimed |
| US-20090215837-A1 | ADMINISTRATION OF PYRIDINEDICARBOXYLIC ACID COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF HUMAN KERATINOUS FIBERS AND/OR ARRESTING THEIR LOSS | L'OREAL | 2009-08-27 | — | — | US | claimed |
| WO-2021121294-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2021-06-24 | — | — | WO | disclosed |
| EP-3162802-B1 | 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME | NIHON MEDIPHYSICS CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-10358434-B2 | 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicament containing same | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2019-07-23 | — | — | US | disclosed |
| US-20190169169-A1 | 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICAMENT CONTAINING SAME | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-10189815-B2 | 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicine containing same | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2019-01-29 | — | — | US | disclosed |
| US-9809586-B2 | Inhibitors of collagen prolyl 4-hydroxylase | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170158668-A1 | 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2017-06-08 | — | — | US | disclosed |
| EP-3162802-A1 | 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME | Nihon Medi-Physics Co., Ltd. (JP) | 2017-05-03 | — | — | EP | disclosed |
| WO-2016160706-A1 | INHIBITORS OF COLLAGEN PROLYL 4-HYDROXYLASE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-10-06 | — | — | WO | disclosed |
| US-5780676-A | BICYCLIC BENZYL, PYRIDINYL, THIOPHENE, FURANYL, PYRROLE, AND POLYENOIC ACID DERIVATIVES | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0678087-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0678086-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0637297-A4 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS. | LIGAND PHARM INC (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995004036-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| EP-0637297-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994015901-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994015902-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169169-A1 | 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICAMENT CONTAINING SAME | XDH, CYP11B2, GOT2 | GABRP 1933/4885GABRD 2436/4885GABRA1 1671/4885 |
| US-20170158668-A1 | 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME | XDH, REN, BRD4 | GABRP 1912/4885GABRD 2919/4885GABRA1 1279/4885 |
| US-10358434-B2 | 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicament containing same | XDH, CYP11B2, GOT2 | GABRP 1933/4885GABRD 2436/4885GABRA1 1671/4885 |
| US-10189815-B2 | 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicine containing same | XDH, REN, BRD4 | GABRP 1912/4885GABRD 2919/4885GABRA1 1279/4885 |
| US-20090215837-A1 | ADMINISTRATION OF PYRIDINEDICARBOXYLIC ACID COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF HUMAN KERATINOUS FIBERS AND/OR ARRESTING THEIR LOSS | AKR1C3, MC1R, KRT18 | GABRP 1811/4885GABRD 568/4885GABRA1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.